Table 3 Review of uDCD studies
Authors, Date, Country | Type of studies, Date of the study | Patient included, Organs procured | Inclusion criteria uDCD | Outcomes |
|---|---|---|---|---|
De Antonio et al., 2007, Spain | Retrospective | 54, | *Absence neoplasia, systemic diseases | *31,5% effective donors |
2002–2006 | Lungs | *1–55 years | *17 lungs transplanted | |
| Â | Â | Â | *Witnessed CA | *53% PNF |
|  |  |  | *No flow < 15 min |  |
|  |  |  | *WIT < 120 min |  |
| Â | Â | Â | *No traumatic massive bleeding | Â |
Mateos-Rodriguez et al., | Retrospective | 28, | *Absence neoplasia, systemic diseases | *39 kidneys transplanted |
2010, Spain | January 2008–April 2009 | Kidneys | *1—55 years | *5,1% PNF |
| Â | Â | Â | *Witnessed CA | Â |
|  |  |  | *No flow < 15 min |  |
|  |  |  | *Arrival hospital < 90 min after CA |  |
| Â | Â | Â | *No traumatic massive bleeding | Â |
Fondevila et al., | Retrospective | 290, | *Absence neoplasia, systemic diseases | *50% effective donors |
2012, Spain | April 2002–December 2010 | Liver | *1—65 years | *34 livers transplantation |
| Â | Â | Â | *Witnessed CA | *82% 1Â year graft survival |
|  |  |  | *No flow < 15 min |  |
|  |  |  | *Arrival hospital < 90 min after CA |  |
| Â | Â | Â | *No traumatic massive bleeding | Â |
Mateos-Rodriguez et al., | Retrospective | 214, | *Absence neoplasia, systemic diseases | *73,9% effective donors |
2012, Spain | January 2005–April 2010 | Kidneys, Liver and Lungs | *1—55 years | *302 organs transplanted |
| Â | Â | Â | *Witnessed CA | *Functionality rate: 91% for kidneys, 75% for livers |
|  |  |  | *No flow < 15 min |  |
|  |  |  | *Arrival hospital < 90 min after CA |  |
| Â | Â | Â | *No traumatic massive bleeding | Â |
Hoogland et al., | Retrospective | Unknown, | *Absence neoplasia, systemic diseases | *83 effective donors |
2011, Nederlands | January 1981–January 2008 | Kidneys | * < 65 years | *138 kidneys transplanted |
| Â | Â | Â | *Witnessed CA | *22% PNF |
|  |  |  | *CPR < 45 min (< 90 min in donors < 50 years) | *63% 5 year graft survival |
|  |  |  | *Time between cessation of resuscitation and start of in situ preservation < 45 min |  |
Peters-Sangers et al., | Retrospective | 133, | *Absence neoplasia, systemic diseases | *49,6% effective donors |
2017, Nederlands | January 2002–January 2012 | Kidneys | * < 65 years | *97 kidneys transplanted |
| Â | Â | Â | *Witnessed CA | *19,6% PNF |
|  |  |  | *No flow < 20 min | *60% 5 year graft survival |
|  |  |  | *Resuscitation < 90 min after CA |  |
|  |  |  | *WIT < 135 min |  |
Lazzeri et al., | Retrospective | 25, | *15–65 years | Unknown |
2020, Italy | June 2016–December 2018 | Unknown | *Witnessed CA |  |
| Â | Â | Â | *Relatives are present | Â |
|  |  |  | *No flow < 20 min |  |
|  |  |  | *CA—hospital time < 90 min |  |
|  |  |  | *WIT < 150 min |  |
Fieux et al., | Prospective | 63, | *Absence neoplasia, systemic diseases | *43% effective donors |
2009, France | February 2007–June 2008 | Kidneys | *18—55 years | *31 kidneys transplanted |
| Â | Â | Â | *Witnessed and refractory CA | *90% 6Â months graft survival |
|  |  |  | *No flow < 30 min |  |
|  |  |  | *WIT < 150 min |  |
Champigneulle et al. | Prospective | 126, | *Absence neoplasia, systemic diseases | *16,9% effective donors |
2015, France | 2010– 2012 | Livers | *18–54 years | *11 livers transplanted |
| Â | Â | Â | *Refractory CA | *27% PNF |
|  |  |  | *No flow < 15 min | *82% 1 year graft survival |
|  |  |  | *WIT < 150 min |  |
Dupriez et al., | Retrospective | 39, | *Absence neoplasia, systemic diseases | *51% effective donors |
2014, Belgium | 1999–2014 | Kidneys | * < 65 years | *25 kidneys transplanted |
| Â | Â | Â | *Witnessed and refractory CA | *5% PNF |
|  |  |  | *No flow < 30 min | *86% 1 year graft survival |
|  |  |  | *WIT < 120 min |  |